Oftalpharma srl

What Oftalpharma srl does

Oftalpharma S.r.l. is an Italian pharmaceutical company headquartered in Prato, Tuscany, operating in the ophthalmic field since 2004 as part of the MediBase Group. It develops, manufactures, and commercializes two product categories: dietary supplements (tablets and capsules) including Maculareds (macular degeneration), Miodesol (vitreous body degeneration), Ocuvase and Reticlar (microcirculation), and Emosid (iron deficiency); and CE-marked medical devices (Class I, IIa, IIb) including the Blefavis eyelid hygiene line (gel, wipes, sterile wipes), Zixol ophthalmic drops (Patent N.0001388403, hyaluronic acid + zinc sulfate), Solidra and Solidra Plus tear substitutes, and NebuLIP ophthalmic spray. Its differentiated technology rests on patented formulations — notably Phytobilayer® liposomal encapsulation for Emosid (peer-reviewed to deliver over 40% iron absorption vs. 15-35% for competitors) and the Zixol hyaluronic acid/zinc combination — supported by clinical collaborations with the Universities of Siena and Ferrara.

The company operates a hybrid go-to-market model: in Italy it sells through a dedicated network of medical representatives (informatori medici) calling on ophthalmologists, hospitals, and pharmacies, supplemented by a direct-to-consumer e-commerce shop (oftalpharmashop.it); internationally it seeks distributors capable of importing, registering, and commercializing products in European, CIS, and MENA markets, with 4B climate zone stability data enabling tropical market entry. Leadership is led by CEO Dott. Andrea Mangiapane alongside a small management team (12 total employees) covering business development, international sales, administration, and product management. Revenue is not publicly disclosed; the company is privately held within the MediBase Group with no disclosed venture capital or private equity investment.

Name

Oftalpharma srl

Legal name

Oftalpharma S.r.l.

Website

https://oftalpharma.it

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Oftalpharma S.r.l. is an Italian pharmaceutical company, founded in 2004 and part of MediBase Group, that develops and commercializes CE-marked ophthalmic medical devices and dietary supplements for ocular conditions, serving ophthalmologists, pharmacies, and international distributors.

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)

akta.pro secondary industries

Herbal & Botanical Supplements (CRADAGAD), Antibacterial & Medicated Cleansers (e.g., Acne, Antifungal, Antiseptic) (CRABAEAH)

Keywords

• Ophthalmic dietary supplements
• CE-marked eye drops
• Eyelid hygiene products
• Ophthalmic medical devices
• Tear substitutes

Headquarters

HQ city

Prato

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Dietary Supplements (Integratori Alimentari): Production and sale of dietary supplements in tablet and capsule form, including Maculareds (macular degeneration), Miodesol (vitreous degeneration), Ocuvase (microcirculation), Reticlar (microcirculation/bioflavonoids), and Emosid (iron deficiency). Revenue is generated through pharmacy and medical channels, with a continuously expanding product catalog.
2. CE-Marked Medical Devices: Production and commercialization of medical devices including eye drops (Zixol, Solidra, Solidra Plus), eyelid wipes (Blefavis Salviette, Blefavis Salviette Sterili), gels (Blefavis Gel, Blefavis Gel con Pantenolo), and ophthalmic spray (NebuLIP). These Class I, IIa, and IIb devices are sold through medical representatives and pharmacies.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Oftalpharma S.r.l. develops, manufactures, and commercializes dietary supplements (tablets and capsules) and CE-marked medical devices (eye drops, eyelid wipes, gels, ophthalmic sprays) dedicated to the ophthalmic sector. The portfolio covers eyelid hygiene (Blefavis line), tear substitutes and corneal protection (Zixol, Solidra, Solidra Plus, NebuLIP), and supplements for macular degeneration, vitreous body degeneration, microcirculation, and iron deficiency (Emosid, Maculareds, Miodesol, Ocuvase, Reticlar). Products are formulated with standardized botanical extracts combined with proprietary delivery technologies such as Phytobilayer® liposomal encapsulation and the patented Zixol formulation (Patent N.0001388403).

Product overview

Oftalpharma S.r.l. is an Italian pharmaceutical company operating in ophthalmology since 2004, part of the MediBase Group. The product portfolio consists of two main categories: (1) Food Supplements (integratori alimentari) including MACULAREDS, MIODESOL, OCUVASE, RETICLAR, Tuxopirina, and Echitus for conditions such as macular degeneration, vitreous body degeneration, microcirculation support, and respiratory health; and (2) Medical Devices CE marked (colliri, salviette oculari e gel) including BLEFAVIS GEL, BLEFAVIS gel con Pantenolo, BLEFAVIS Salviette, BLEFAVIS Salviette sterili, NEBULIP SPRAY, SOLIDRA, SOLIDRA PLUS, ZIXOL Gocce sterili, and ZIXOL Monodose fiale sterili for ocular surface care, tear substitutes, eyelid hygiene, and dry eye treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• MACULAREDS Dietary supplement containing Vitamin C, Vitamin E, Zinc, Copper, Selenium, Coenzyme Q10, Lipoic Acid, Taurine, Lutein and Zeaxanthin, formulated for prevention and treatment of macular degeneration. Targeted at patients with age-related macular concerns via ophthalmologists and pharmacy channels.
• MIODESOL Dietary supplement containing Magnesium, Lipoic Acid, Bromelain with Potassium and Curcuminoids, targeting oxidative degeneration of connective tissues such as the vitreous body. Sold through medical representatives and pharmacies for ophthalmology patients.
• OCUVASE Food supplement with titrated extracts of Vitis vinifera, Centella, Ginkgo, Orthosiphon, Lespedeza and Ruscus, providing vascular, anti-inflammatory, draining and anti-oedemigenous activity for ophthalmology patients.
• RETICLAR Dietary supplement containing Vitamin C and Vitamin E with extracts of Maritime Pine, Blueberry, Ginkgo biloba and red grape, indicated for microcirculation alterations affecting ocular health.
• EMOSID Dietary supplement for iron deficiency anemia formulated with ferrous sulphate and Vitamin C encapsulated within the patented Phytobilayer® liposomal bilayer structure, delivering over 40% iron absorption versus 15-35% for competing formulations and reducing gastrointestinal side effects.
• Tuxopirina Dietary supplement syrup containing Vitamin B6, Iron and Zinc with White Horehound, Grindelia, Thyme, Spirea and Eleutherococcus, indicated as an adjuvant in the treatment of respiratory tract diseases.
• Echitus Food supplement syrup containing Vitamin B6, Iron, Zinc with Propolis and extracts of Altea, Horehound, Echinacea and Thyme, formulated for treatment and prevention of respiratory diseases.
• BLEFAVIS GEL Class I medical device periocular detergent gel for daily cleaning of eyelids and eyelashes, hypoallergenic with iso-lacrimal pH, normalizing bacterial load with Aloe and Mallow extracts. For ophthalmology patients and consumers managing eyelid hygiene.
• BLEFAVIS Gel con Pantenolo Class I medical device gel for eyelid and eyelash cleaning with Panthenol, iso-lacrimal pH, normalizing bacterial levels, providing moisturizing and wound-healing coadjuvant action.
• BLEFAVIS Salviette Class I medical device, disposable periocular wipes for daily cleaning of sensitive and seborrheic eyelids with refreshing, emollient and cleanser actions.
• BLEFAVIS Salviette Sterili Class IIa medical device, sterile disposable periocular wipes usable on open wounds and abrasions with detergent and emollient characteristics; pediatric indications from age 4 supported by stability studies.
• NEBULIP SPRAY Class IIb medical device ophthalmic spray with hypotonic saline solution based on liposomes and thermal water, providing relief from burning, dryness, redness and fatigue; usable on closed eyelids.
• SOLIDRA Class IIa medical device, multidose sterile tear substitute with pre-dosed drops for corneal protection, containing 0.16% hyaluronic acid, transparent and viscoelastic.
• SOLIDRA PLUS Class IIb medical device, sterile slightly hypotonic saline ophthalmic solution combining cross-linked and linear sodium hyaluronate for enhanced lubrication and hydration of the ocular surface.
• ZIXOL Gocce Sterili Class IIa medical device, sterile ophthalmic solution, preservative-free, moisturizing and lubricating with High Molecular Weight Hyaluronic Acid and Zinc Sulfate, providing corneal protection and tear film support.
• ZIXOL Monodose Fiale Sterili Class IIa medical device, preservative-free sterile ophthalmic solution in multidose vials containing High Molecular Weight Hyaluronic Acid and Zinc Sulfate for corneal protection, based on the patented Zixol formulation (Patent N.0001388403).

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• University of SienaflagshipStrategic or Co-development Partner · 1 March 2024Collaborative research partnership with the University of Siena's Department of Chemical and Pharmaceutical Sciences resulted in a published study (March 2024, Journal of Drug Delivery Science and Technology) validating the exceptional bioavailability of iron in Emosid supplement (over 40% absorption vs. 15-35% for competitors). This peer-reviewed scientific evidence supports product claims and differentiation.
• University of FerraracoreStrategic or Co-development Partner · 1 May 2023Stability study conducted at the Department of Chemical, Pharmaceutical and Agricultural Sciences (May-June 2023) validated that Blefavis Sterile Wipes maintain quality specifications after repeated temperature changes (25°C to 4°C) and after heating at 40°C. This study enabled expansion of usage instructions to include hot and cold compress applications and pediatric indications from age 4.
• Gruppo MediBasecoreOthersOftalpharma Srl is part of the MediBase Group (Gruppo MediBase), a broader Italian pharmaceutical group operating in the ophthalmic sector. This corporate affiliation provides institutional backing, shared resources, and cross-brand synergies within the nutraceutical and pharmaceutical space. The group also includes Medibase.it for nutriceuticals.

Scale indicators3 records

Recent moves5 records

Expansion highlights10 records

Emerging players

• Nicox SA: European ophthalmic specialty company focused on therapeutics for ocular conditions. Comparable as a smaller, research-driven ophthalmic player with niche products targeting glaucoma, dry eye, and inflammation, overlapping with Oftalpharma's therapeutic focus.
• Medivis: Italian ophthalmic medical device and pharmaceutical company. Comparable as another Italy-based ophthalmic specialist with overlapping product categories in ocular surface and eyelid care, competing for similar domestic and select international channels.

Broad incumbents

• Dompé farmaceutici: Italian biopharmaceutical company with an ophthalmic division. Comparable as an Italian-headquartered pharma player with eye care products, though significantly larger and more diversified across multiple therapeutic areas beyond ophthalmology.
• Recordati: Italian-headquartered multinational pharmaceutical group with ophthalmic products. Comparable as an Italian pharma incumbent with ophthalmic offerings, though broader and far larger in scale across multiple therapeutic areas.
• Bausch + Lomb: Global ophthalmic pharmaceutical and medical device giant. Comparable in ophthalmic product categories (eye drops, dry eye, ocular surface) but vastly larger scale with full global sales infrastructure, serving as the dominant competitor in the categories Oftalpharma operates in.
• Santen Pharmaceutical: Japanese-headquartered global ophthalmic specialty pharmaceutical company. Comparable in focus on prescription and OTC ophthalmic products including dry eye and ocular surface treatments, but with significantly greater international footprint and R&D resources.
• Allergan (AbbVie): Global ophthalmic pharmaceutical powerhouse (now part of AbbVie) with leading products in dry eye (Restasis), glaucoma, and ocular surface. Comparable in ophthalmic therapeutic categories but at incomparably greater scale, marketing reach, and pipeline depth.

Direct peers

• Théa Pharmaceuticals: French-headquartered independent ophthalmic pharmaceutical company. Comparable as an independent, family-controlled specialty pharma focused on ophthalmology with a strong portfolio of eye drops, dry eye treatments, and eyelid hygiene products distributed across Europe and select international markets.
• Sifi SpA: Italian ophthalmic specialty pharma company headquartered in Catania. Both are mid-sized Italian players focused exclusively on ophthalmology with overlapping portfolios of eye drops, eyelid hygiene, and ocular surface products, competing for the same ophthalmologist and pharmacy channels in Italy and select international markets.
• Horus Pharma: French independent ophthalmic pharmaceutical company specializing in eye drops, eyelid hygiene, and dry eye products. Comparable as a similar-sized, independent European ophthalmic specialty player with a comparable product mix and reliance on distributor networks for international reach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/oftalpharma-srl-and-medibase-srl-group

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oftalpharma srl